×
Newsmax TV & Webwww.newsmax.comFREE - In Google Play
VIEW
×
Newsmax TV & Webwww.newsmax.comFREE - On the App Store
VIEW
Tags: binge | eating | drug | vyvanse

Drug That Fights Binge Eating OKd by FDA

Saturday, 31 January 2015 10:04 AM

The U.S. Food and Drug Administration on Friday approved Shire's stimulant Vyvanse to treat binge-eating disorder, the first product to be approved for the condition.
 
Vyvanse, which is currently approved to treat attention deficit hyperactivity disorder, generated sales of more than $1 billion in the first nine months of last year.

Dr. Flemming Ornskov, the company's chief executive officer, said in an interview that Shire's goal is to generate overall sales of $10 billion by 2020. Of that, he expects $200 million to $300 million to come from Vyvanse for binge-eating.

Peak annual sales could be significantly higher, he added, as awareness of the condition increases.

Binge-eating disorder, characterized by repeated episodes of uncontrolled eating, accompanied by guilt and shame, affects roughly 2.8 million people in the United States, according to Shire.

"Binge eating can cause serious health problems and difficulties with work, home, and social life," said Dr. Mitchell Mathis, director of the FDA's division of psychiatry products. "The approval of Vyvanse provides physicians and patients with an effective option to help curb episodes of binge eating."

In clinical studies, patients taking Vyvanse were shown to have significantly fewer binge days per week than those taking a placebo.

At the time of entry to the study, the average number of binge days per week was 4.79. At week 12, average binge days per week had fallen to less than one. Patients taking a placebo, by comparison, saw a reduction of little more than 2 days a week.

Vyvanse is an amphetamine which, like other amphetamines, carries the potential for abuse and addiction. They also have been associated with increase blood press sure and heart rate, sudden death, stroke, heart attack, insomnia and psychiatric side effects such as hallucinations and mania.

The drug is not approved for weight loss.

© 2022 Thomson/Reuters. All rights reserved.


Health-News
The U.S. Food and Drug Administration on Friday approved Shire's stimulant Vyvanse to treat binge-eating disorder, the first product to be approved for the condition. Vyvanse, which is currently approved to treat attention deficit hyperactivity disorder,generated sales of more...
binge, eating, drug, vyvanse
299
2015-04-31
Saturday, 31 January 2015 10:04 AM
Newsmax Media, Inc.

Sign up for Newsmax’s Daily Newsletter

Receive breaking news and original analysis - sent right to your inbox.

(Optional for Local News)
Privacy: We never share your email address.
Join the Newsmax Community
Read and Post Comments
Please review Community Guidelines before posting a comment.
 
Find Your Condition
Get Newsmax Text Alerts
TOP

The information presented on this website is not intended as specific medical advice and is not a substitute for professional medical treatment or diagnosis. Read Newsmax Terms and Conditions of Service.

Newsmax, Moneynews, Newsmax Health, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, and Newsmax World are trademarks of Newsmax Media, Inc.

NEWSMAX.COM
© Newsmax Media, Inc.
All Rights Reserved
NEWSMAX.COM
© Newsmax Media, Inc.
All Rights Reserved